Calquence and Chronic obstructive pulmonary disease - a phase IV clinical study of FDA data

Summary:

Chronic obstructive pulmonary disease is reported as a side effect among people who take Calquence (acalabrutinib), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Imbruvica, and have Chronic lymphocytic leukaemia.

The phase IV clinical study analyzes which people have Chronic obstructive pulmonary disease when taking Calquence. It is created by eHealthMe based on reports of 5,620 people who have side effects when taking Calquence from the FDA, and is updated regularly.

What is Calquence?

Calquence has active ingredients of acalabrutinib. eHealthMe is studying from 5,627 Calquence users. Check the latest studies of Calquence.

What is Chronic obstructive pulmonary disease?

Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe) is found to be associated with 1,807 drugs and 2,206 conditions by eHealthMe. Check the latest studies of Chronic obstructive pulmonary disease.

On Jul, 20, 2026

5,620 people reported to have side effects when taking Calquence.
Among them, 13 people (0.23%) have Chronic obstructive pulmonary disease.

Could Calquence cause Chronic obstructive pulmonary disease?

Among these 13 people:

How long have people been on Calquence when they have Chronic obstructive pulmonary disease? *

What is the gender of people who have Chronic obstructive pulmonary disease when taking Calquence? *

female: 72.73 %
male: 27.27 %

What is the age of people who have Chronic obstructive pulmonary disease when taking Calquence? *

What are other drugs people take besides Calquence? *

What are other side effects people have besides Chronic obstructive pulmonary disease? *

Dyspnea (difficult or laboured breathing): 4 people, 30.77%
Pneumonia: 4 people, 30.77%
Back Pain: 3 people, 23.08%
Joint Pain: 3 people, 23.08%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 3 people, 23.08%
Thrombosis (formation of a blood clot inside a blood vessel): 2 people, 15.38%
Abdominal Pain: 2 people, 15.38%
Pain: 2 people, 15.38%
Fatigue (feeling of tiredness): 2 people, 15.38%
Cough: 2 people, 15.38%

What are the existing conditions these people have? *

Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 6 people, 46.15%
Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 3 people, 23.08%
Eye Disorder: 1 person, 7.69%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 1 person, 7.69%
Chronic Lymphocytic Leukaemia Recurrent (repeated cancer of blood cells known as lymphocytes): 1 person, 7.69%
Burkitt Lymphoma (cancer of the lymphatic system): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Calquence and have Chronic obstructive pulmonary disease?

- Check whether Chronic obstructive pulmonary disease is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Calquence:

Calquence (5,627 reports)

Browse all side effects of Calquence:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Chronic obstructive pulmonary disease:

Chronic obstructive pulmonary disease (1,807 drugs)

Browse all the conditions that are associated with Chronic obstructive pulmonary disease:

Chronic obstructive pulmonary disease (2,206 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on acalabrutinib (the active ingredients of Calquence) and Calquence (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.